Adapalene 0.1%/benzoyl peroxide 2.5% gel: A review of its use in the treatment of acne vulgaris in patients aged ≥12 years

American Journal of Clinical Dermatology

Volumn 12, Issue 6, 2011, Pages 407-420

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acne vulgaris; Adapalenebenzoyl peroxiD.E.; Adis Drug Evaluations

Indexed keywords

ADAPALENE; ADAPALENE PLUS BENZOYL PEROXIDE; BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; DOXYCYCLINE HYCLATE; DRUG VEHICLE; LYMECYCLINE; RETINOIC ACID; TACTUO; TAZAROTENE; UNCLASSIFIED DRUG;

ACNE VULGARIS; AGE; BURN; COMEDO; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; EVENING DOSAGE; GASTROINTESTINAL DISEASE; GEL; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; PAPULE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SKIN DEFECT; SKIN IRRITATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; BENZOYL PEROXIDE; CHILD; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; GELS; HUMANS; NAPHTHALENES; TIME FACTORS;

EID: 80053538898     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11208170-000000000-00000     Document Type: Review

References (55)

1. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003; 63 (15): 1579-96 (Pubitemid 36976140)
2. Yentzer BA, Hick J, Reese EL, et al. Acne vulgaris in the United States: a descriptive epidemiology. Cutis 2010 Aug; 86 (2): 94-9
3. Gollnick HPM, Finlay AY, Shear N. Canwe define acne as a chronic disease? If so, how and when? Am J Clin Dermatol 2008; 9 (5): 279-84
4. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol 2009 May; 60 (5 Suppl.): S1-50
5. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006 Sep; 118 (3): 1188-99 (Pubitemid 46090063)
6. Zuliani T, Khammari A, Chaussy H, et al. Ex vivo demonstration of a synergistic effect of adapalene and benzoyl peroxide on inflammatory acne lesions. Exp Dermatol. Epub 2011 Jul 2
7. Tan J, Gollnick HP, Loesche C, et al. Synergistic efficacy of adapalene 0.1%- benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 2011 Aug; 22 (4): 197-205
8. Ghali F, Kang S, Leyden J, et al. Changing the face of acne therapy. Cutis 2009 Feb; 83 (2 Suppl.): 4-15
9. Galderma Laboratories. Epiduo- (adapalene and benzoyl peroxide) gel 0.1%/ 2.5% for topical use: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022320s001lbl. pdf [Accessed 2011 Jun 14]
10. Galderma (UK) Ltd. Epiduo 0.1%/2.5% gel: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/ EMC/medicine/22679/SPC/Epiduo+0.1++2.5++Gel/ [Accessed 2011 Jun 14].
11. Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs 2004; 64 (13): 1465-78 (Pubitemid 38980458)
12. Layton AM, Eady EA. Benzoyl peroxide and adapalene fixed combination: a novel agent for acne. Br J Dermatol 2009 Nov; 161 (5): 971-6
13. Tan JKL. Adapalene 0.1%and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris. Skin Therapy Lett 2009 Jul/Aug; 14 (6): 4-5
14. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol 2005 Jan/Feb; 4 (1): 41-7
15. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol 2003; 4 (2): 75-80 (Pubitemid 36259516)
16. Asselineau D, Cavey M-T, Shroot B, et al. Control of epidermal differentiation by a retinoid analogue unable to bind to cytosolic retinoic acid-binding proteins (CRABP). J Invest Dermatol 1992 Feb; 98 (2): 128-34
17. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S96-103
18. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998 Aug; 39 (2 Pt 3): S17-24 (Pubitemid 28367282)
19. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 5-12 (Pubitemid 34036865)
20. Shroot B, Michel S, Allec J, et al. A new concept of drug delivery for acne. Dermatology 1998; 196 (1): 165-70 (Pubitemid 28116068)
21. Imahiyerobo-Ip JI, Dinulos JG. Changing the topography of acne with topical medications. Curr Opin Pediatr 2011; 23 (1): 121-5
22. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007 Jun; 16 (6): 500-6 (Pubitemid 46845393)
23. Vega B, Jomard A, Michel S. Regulation of humanmonocyte Toll-like receptor 2 (TLR2) expression by adapalene [abstract no. P1-39]. J Eur Acad Dermatol Venerol 2002 Oct; 16 Suppl. 1: 123-4
24. Michel S, Jomard A, Démarchez M. Pharmacology of adapalene. Br J Dermatol 1998 Oct; 139 Suppl. 52: 3-7 (Pubitemid 28475276)
25. Center for Drug Evaluation and Research. Application number: 22-320: pharmacology review(s) [online]. Available from URL: http://www.access data.fda.gov/drugsat.fda-docs/nda/2008/022320s000-PharmR.pdf [Accessed 2011 Jun 14].
26. Mills OH, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10%benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986 Dec; 25 (10): 664-7 (Pubitemid 17210594)
27. Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 2003; 42 (14): 1287-304 (Pubitemid 37491489)
28. Cove JH, Holland KT. The effect of benzoyl peroxide on cutaneous microorganisms in vitro. J Appl Bacteriol 1983 Jun; 54 (3): 379-82 (Pubitemid 13066056)
29. Bojar RA, Cunliffe WJ,Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995 Feb; 132 (2): 204-8
30. Farmery MR, Jones CE, Eady EA, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5 (2): 63-5 (Pubitemid 24216150)
31. Leyden JJ, Preston N, Osborn C, et al. In-vivo effectiveness of adapalene 0.1%/benzoyl peroxide 2.5% gel on antibiotic-sensitive and resistant Propionibacterium acnes. J Clin Aesthet Dermatol 2011 May; 4 (5): 22-6
32. Caron D, Clucas A, Dunsire JP, et al. Radiolabelled adapalene is poorly absorbed after topical application of adapelene 0.1% gel [abstract no. P384]. J Eur Acad Dermatol Venerol 1998 Sep; 11 Suppl. 2: S275-6
33. Allec J, Chatelus A, Wagner N. Skin distribution and pharmaceutical aspects of adapalene gel. J Am Acad Dermatol 1997 Jun; 36 (6 Pt 2): S119-125 (Pubitemid 27265893)
34. Center forDrug Evaluation andResearch.Application number 22-320: clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsat.fda-docs/nda/ 2008/022320s000-Clin PharmR.pdf [Accessed 2011 Jun 14].
35. Nacht S, Yeung D, Beasley JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol 1981 Jan; 4 (1): 31-7 (Pubitemid 11137313)
36. Gollnick HPM, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009 Nov; 161 (5): 1180-9
37. Stein Gold L, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009 Aug; 84 (2): 110-6
38. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-benzoyl peroxide, a fixeddose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007 Nov; 57 (5): 791-9 (Pubitemid 47553072)
39. Eichenfield LF, Jorizzo JL, Dirschka T, et al. Treatment of 2,453 acne vulgaris patients aged 12-17 years with the fixed-dose adapalene-benzoyl peroxide combination topical gel: efficacy and safety. J Drugs Dermatol 2010 Nov; 9 (11): 1395-401
40. Feldman SR, Tan J, Poulin Y, et al. The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. J Am Acad Dermatol 2011 Jun; 64 (6): 1085-91
41. Zouboulis CC, Fischer TC, Wohlrab J, et al. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Cutis 2009 Oct; 84 (4): 223-9
42. Dréno B, KaufmannR, Talarico S, et al. Combination therapy with adapalenebenzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicenter, randomised, double-blind controlled study. Br J Dermatol 2011 Aug; 165 (2): 383-90
43. Stein Gold L, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, doubleblind study of adapalene 0.1%-benzoyl peroxide 2.5%fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 2010 Feb; 85 (2): 94-104
44. Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol 2011 Jun; 164 (6): 1376-82
45. Troielli PA, Asis B, Bermejo A, et al. Community study of fixed-combination adapalene 0.1% and benzoyl peroxide 2.5% in acne. Skinmed 2010 Jan/Feb; 8 (1): 17-22
46. Pariser DM,Westmoreland P,Morris A, et al. Long-termsafety and efficacy of a unique fixed-dose combination gel of adapalene 0.1%and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol 2007 Sep; 6 (9): 899-905
47. Callender VD, Preston N, Osborn C, et al. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol 2010 Aug; 3 (8): 15-9
48. Loesche C, Pernin C, Poncet M. Adapalene 0.1%and benzoyl peroxide 2.5%as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. Eur J Dermatol 2008 Sep-Oct; 18 (5): 524-6
49. Leyden JJ, Nighland M, Rossi AB, et al. Irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel. J Drugs Dermatol 2010 Aug; 9 (8): 998-1003
50. Andres P, Pernin C, Poncet M. Adapalene-benzoyl peroxide once-daily, fixeddose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants. Cutis 2008 Mar; 81 (3): 278-84
51. Webster GF. Evidence-based review: fixed-combination therapy and topical retinoids in the treatment of acne. J Drugs Dermatol 2011 Jun; 10 (6): 636-44
52. Dréno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010 Apr; 49 (4): 448-56
53. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007 Apr; 56 (4): 651-63 (Pubitemid 46400177)
54. Ortho Dermatologics. Retin-A Micro® (tretinoin) gel microsphere 0.1% and 0.04%: US prescribing information [online]. Available from URL: http:// www.retinamicro.com/sites/default/files/RetinAMicro.pdf#zoom=200 [Accessed 2011 Jun 17]
55. Mylan Pharmaceuticals Inc. Avita® (tretinoin) gel 0.025%: US prescribing information [online]. Available from URL: http://www.drugs.com/pro/ avita. html?printable=1 [Accessed 2011 Jun 21]